Literature DB >> 8014484

Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection.

M Ericsson1, G Sandström, A Sjöstedt, A Tärnvik.   

Abstract

The humoral and cell-mediated immune responses to the facultative intracellular pathogen Francisella tularensis were studied in subjects who had tularemia 25 years earlier. Serum agglutinin titers were low. Of 53 subjects, only 2 had a titer > 40. The F. tularensis-induced T cell response, on the other hand, was vigorous and in fact similar in magnitude to the response to purified protein derivative (PPD) of Mycobacterium tuberculosis. T cells from 44 of 52 subjects showed a significant (P < .05) proliferative response in vitro to each of four membrane proteins of F. tularensis. Only 2 subjects did not respond to any of the proteins. In most cultures from 18 subjects tested, interferon-gamma was produced in response to the proteins. During the last 25 years, tularemia has been reported only rarely in the region where the subjects lived, suggesting that an antigen-specific T cell response may persist after tularemia independently of reexposure to F. tularensis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014484     DOI: 10.1093/infdis/170.1.110

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  The proportion of circulating gammadelta T cells increases after the first week of onset of tularaemia and remains elevated for more than a year.

Authors:  M Kroca; A Tärnvik; A Sjöstedt
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Characterization of Francisella tularensis outer membrane proteins.

Authors:  Jason F Huntley; Patrick G Conley; Kayla E Hagman; Michael V Norgard
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

3.  Kinetics of the immune response associated with tularemia: comparison of an enzyme-linked immunosorbent assay, a tube agglutination test, and a novel whole-blood lymphocyte stimulation test.

Authors:  Henrik Eliasson; Per Olcén; Anders Sjöstedt; Margareta Jurstrand; Erik Bäck; Sören Andersson
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

4.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

5.  Persistence of cell-mediated immunity three decades after vaccination with the live vaccine strain of Francisella tularensis.

Authors:  Kjell Eneslätt; Cecilia Rietz; Patrik Rydén; Svenja Stöven; Robert V House; Lawrence A Wolfraim; Arne Tärnvik; Anders Sjöstedt
Journal:  Eur J Immunol       Date:  2011-02-21       Impact factor: 5.532

6.  Evaluation of an immunochromatographic test for rapid and reliable serodiagnosis of human tularemia and detection of Francisella tularensis-specific antibodies in sera from different mammalian species.

Authors:  W Splettstoesser; V Guglielmo-Viret; E Seibold; P Thullier
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

7.  Immunoproteomic analysis of the human antibody response to natural tularemia infection with Type A or Type B strains or LVS vaccination.

Authors:  Kelly M Fulton; Xigeng Zhao; Mireille D Petit; Sara L N Kilmury; Lawrence A Wolfraim; Robert V House; Anders Sjostedt; Susan M Twine
Journal:  Int J Med Microbiol       Date:  2011-08-27       Impact factor: 3.473

Review 8.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

9.  Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.

Authors:  Hua Shen; Gregory Harris; Wangxue Chen; Anders Sjostedt; Patrik Ryden; Wayne Conlan
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

10.  Vaccination with an attenuated strain of Francisella novicida prevents T-cell depletion and protects mice infected with the wild-type strain from severe sepsis.

Authors:  Jyotika Sharma; Qun Li; Bibhuti B Mishra; Michelle J Georges; Judy M Teale
Journal:  Infect Immun       Date:  2009-07-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.